Artificial Intelligence is significantly impacting various sectors, yet few domains present as much potential or encounter as many obstacles as its use in regulatory science. In a recent Katalysts Podcast by Katalyze AI, Paul Kim who is a Life Science and Health Policy Advisor, a Food and Drug Lawyer and a Former Congressional staffer, offered his insights on the transformation of regulatory processes by AI, the challenges involved, and the opportunities available to foster global change.
It’s not about being disruptive for the sake of disruption. It’s about being social actors—partners in this journey.
AI’s Growing Role in Drug and Device Regulation
The Challenge of 20th-Century Regulations in a 21st-Century World
One of the most pressing issues is that current laws were designed for conventional technologies. Kim points out that leaders like FDA Commissioner Dr. Robert Califf have acknowledged the need to modernize regulatory frameworks to better align with emerging innovations.
This gap between regulation and technology can lead to inefficiencies in the drug approval process, which is already lengthy and resource-intensive.
Kim warns against underfunding the FDA, noting that diminished resources would force the agency to retreat into a “turtle shell,” stalling progress. Instead, he advocates for robust funding and a collaborative approach that balances innovation with accountability. Katalyze’s collaborative model is essential in ensuring that AI-powered healthcare solutions meet rigorous standards without delaying patient access.
Unlocking Opportunities in Rare Diseases
Rare diseases present unique opportunities for AI to shine. With over 7,000 known rare diseases, AI-driven tools could accelerate drug discovery and enable personalized treatment strategies.
Kim emphasizes the potential of generative AI and advanced analytics to repurpose existing molecules and develop new therapies tailored to specific conditions. However, the financial model for such endeavors remains a challenge. “Health plans won’t pay for inherently experimental treatments,” Kim notes, highlighting the need for innovative funding mechanisms.
Public-Private Collaboration: The Key to Sustainable Innovation
The integration of AI into regulatory science is both a challenge and an opportunity. By fostering collaboration, embracing transparency, and addressing systemic inefficiencies, regulatory agencies can harness AI to drive safer, more efficient healthcare innovation.
Katalyze’s role as a facilitator and innovator ensures that these efforts remain grounded in real-world applications. As Kim aptly states, “It’s not about being disruptive for the sake of disruption. It’s about being social actors—partners in this journey.” The stakes are high, but with the right mix of vision, funding, and collaboration, AI can revolutionize regulatory science and improve outcomes for patients worldwide.
